140 related articles for article (PubMed ID: 28144693)
1. [Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO].
Rexer H; Graefen M
Urologe A; 2017 Feb; 56(2):243-244. PubMed ID: 28144693
[No Abstract] [Full Text] [Related]
2. [A multicentric, randomized, double-blind, placebo-controlled Phase III study of ARN-509 in men with non-metastatic (M0) castration-resistant prostate cancer (SPARTAN): AUO study AP 82/14].
Rexer H; Hammerer P
Urologe A; 2016 Mar; 55(3):395-7. PubMed ID: 26820656
[No Abstract] [Full Text] [Related]
3. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy.
Barata P; Swami U; Agarwal N
Expert Rev Anticancer Ther; 2020 Mar; 20(3):147-150. PubMed ID: 32068456
[No Abstract] [Full Text] [Related]
4. The development of apalutamide for the treatment of prostate cancer.
Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
[TBL] [Abstract][Full Text] [Related]
5. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
6. Apalutamide radio-sensitisation of prostate cancer.
Kakouratos C; Kalamida D; Lamprou I; Xanthopoulou E; Nanos C; Giatromanolaki A; Koukourakis MI
Br J Cancer; 2021 Nov; 125(10):1377-1387. PubMed ID: 34471256
[TBL] [Abstract][Full Text] [Related]
7. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
[TBL] [Abstract][Full Text] [Related]
8. Combined hormone therapy and radiation therapy for locally advanced prostate cancer.
Bolla M; Laramas M;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e30-4. PubMed ID: 21144766
[TBL] [Abstract][Full Text] [Related]
9. [Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for first line chemotherapy (VIABLE) - AUO study AP 78/13].
Rexer H
Urologe A; 2015 Apr; 54(4):555-7. PubMed ID: 25758238
[No Abstract] [Full Text] [Related]
10. [Adjuvant radiotherapy in lymph-node-positive prostate cancer with low tumor burden after radical prostatectomy : Multicenter randomized phase III trial on the effect of adjuvant radio therapy in patients with prostate cancer with or without positive margins after radical prostatectomy (RP) and lymph node metastasis with low tumor burden (micrometastases, ≤ 2 lymph node macrometastases). ART-2 trial AP 61/11 of the AUO].
Rexer H; Bartkowiak D
Urologe A; 2015 Jun; 54(6):871-4. PubMed ID: 26081820
[No Abstract] [Full Text] [Related]
11. [Multimodal therapy of locally advanced prostate cancer].
Heidenreich A; Böhmer D
Urologe A; 2016 Mar; 55(3):333-44. PubMed ID: 26943666
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
Pérez-Ruixo C; Pérez-Blanco JS; Chien C; Yu M; Ouellet D; Pérez-Ruixo JJ; Ackaert O
Clin Pharmacokinet; 2020 Feb; 59(2):229-244. PubMed ID: 31432469
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement.
Schröder FH; Roobol MJ; Boevé ER; de Mutsert R; Zuijdgeest-van Leeuwen SD; Kersten I; Wildhagen MF; van Helvoort A
Eur Urol; 2005 Dec; 48(6):922-30; discussion 930-1. PubMed ID: 16263208
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
15. Apalutamide (Erleada) for prostate cancer.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
[No Abstract] [Full Text] [Related]
16. Risk of biochemical recurrence and timing of radiotherapy in pT3a N0 prostate cancer with positive surgical margin : A single center experience.
Hegemann NS; Morcinek S; Buchner A; Karl A; Stief C; Knüchel R; Corradini S; Li M; Belka C; Ganswindt U
Strahlenther Onkol; 2016 Jul; 192(7):440-8. PubMed ID: 27272660
[TBL] [Abstract][Full Text] [Related]
17. Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Sakamoto S
Int J Urol; 2021 Mar; 28(3):288. PubMed ID: 33327040
[No Abstract] [Full Text] [Related]
18. Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer.
Fletcher SG; Mills SE; Smolkin ME; Theodorescu D
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1092-9. PubMed ID: 16965872
[TBL] [Abstract][Full Text] [Related]
19. Words of wisdom: Re: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study [abstract 3].
Bolla M
Eur Urol; 2013 Sep; 64(3):513. PubMed ID: 23915463
[No Abstract] [Full Text] [Related]
20. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
